1. (p = 0.32 for noninferiority)
BEST
Trial design: Subjects with multivessel coronary disease were randomized to PCI with everolimus-eluting stents (n = 438) vs. CABG (n = 442).
Results
(p = 0.32 for noninferiority)
The study was terminated early in October 2013 due to slow enrollment
Death, MI, or target vessel revascularization (TVR) at 2 years: 11.0% of the PCI group vs. 7.9% of the CABG group (p = 0.32 for noninferiority)
Spontaneous MI: 4.3% vs. 1.6% (p = 0.02), respectively, for PCI vs. CABG
TVR: 11.0% vs. 5.4% (p = 0.003), respectively, for PCI vs. CABG
11.0 %
7.9
Conclusions
Among patients with multivessel coronary disease, PCI was not noninferior to CABG at 2 years
The primary outcome was driven by an excess of spontaneous MI and repeat revascularization procedures in the PCI group
PCI
CABG
Park SJ, et al. N Engl J Med 2015;372: